Consortia Therapeutics develops microbial therapies to prevent and treat human disease and alelrgies.
Our work is based upon evidence-based studies from the Massachusetts Host Microbiome Center and the research of its scientific founders.
- Clinical Benefit. Working with Lynn Bry, M.D., Ph.D. (ConsortiaTx’s founder a Pathologist and world renowned anaerobic microbiologist and mucosal immunologist), Talal Chatila, M.D. (Clinical Immunologist and internationally renowned researcher studying human food allergies; also on Consortia’s SAB), and Georg Gerber, M.D., Ph.D., M.P.H (Pathologist and world-renown computer scientist; also on Consortia’s SAB) at Harvard Medical School, Consortia has licensed rights to the discovery that defined communities of organisms that skew the immune system from promoting allergic responses to becoming tolerant of the formerly allergy-inducing foods. Furthermore, our scientists have been able to administer these organisms to a mouse with a human genetic susceptibility to food allergies and both prevent the allergy from happening, or cure a pre-existing allergy. Administration of these protective organisms specifically prevents the development of food allergies and reversed pre-existing allergies. Our scientists have also identified microbial consortia that promote food allergic responses, which serve as potential diagnostic biomarkers to identify patients with “dysbiosis,” or a microbiota that enhances allergic responses.
- Defined Immunological Benefit. We have defined immune markers that can predict a successful therapeutic response, namely a significant reduction in allergen-specific immunoglobulin E (IgE) after receiving the therapeutic regimen. Furthermore, our team has defined gut and immune targets of the administered consortia that mediate these effects.